Craft

Advanced
  • Home
  •  / Athira Pharma
Athira Pharma

Athira Pharma

Stock Price

$0.5

2024-10-29

Market Capitalization

$18.9 M

2024-10-29

Athira Pharma Summary

Company Summary

Overview
Athira Pharma a drug development company intended to develop therapies for neurodegenerative diseases. The company develops drugs focused on turning brain degeneration into regeneration, achieved by re-establishing lost connections and restoring lost function.
Type
Public
Status
Active
Founded
2011
HQ
Seattle, WA, US | view all locations
Website
https://athira.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Table of Contents

Key People

  • Hans Moebius

    Hans Moebius, Chief Medical Officer

    • Glenna Mileson

      Glenna Mileson, Chief Financial Officer & Corporate Secretary

      • Mark Worthington

        Mark Worthington, General Counsel

        LocationsView all

        2 locations detected

        • Seattle, WA HQ

          United States

          4000 Mason Rd #300

        • Bothell, WA

          United States

          18706 North Creek Pkwy #104

        Athira Pharma Financials

        Summary Financials

        Net income (Q1, 2026)
        ($32.9M)
        Cash (Q1, 2026)
        $32.8M
        EBIT (Q1, 2026)
        ($17.2M)
        Enterprise value
        ($13.3M)

        Competitors and Similar Companies

        Compare competitors

        Footer menu

        Product

        Solutions

        Resources

        Company

        © Craft.co 2026
        Share price data provided by IEX